https://www.selleckchem.com/pr....oducts/etomoxir-na-s
Three thousand five hundred and nineteen (49%) of the patients had received combined ADT and particle therapy. Primarily high-risk (87%), to a lesser extent intermediate-risk (34%) and low-risk patients (12%) received ADT. There were no comparative studies on the effect of ADT in patients treated with particles and no studies identified ADT as an independent prognostic factor related to survival outcomes. The review found no evidence to support that the effects on biochemical disease-free survival and morbidity of combining ADT
Like
Comment
Share
